Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers D > Headlines for Dicerna Pharmaceuticals Inc. > News item |
Dicerna Pharmaceuticals to price initial public offering of stock
Offering finances studies, trials and technology platform development
By Devika Patel
Knoxville, Tenn., Dec. 31 - Dicerna Pharmaceuticals Inc. plans to price an initial public sale of its common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.
Jefferies, Leerink Swann and Stifel are the joint bookrunners.
Proceeds will be used for preclinical studies and clinical trials, technology platform development, working capital and general corporate purposes.
The biopharmaceutical company is based in Watertown, Mass. It expects its shares will trade on the Nasdaq under the symbol "DRNA."
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.